CompanyERNA ERNAWNasdaqCambridge, MA

Ernexa Therapeutics Inc.

Ernexa Therapeutics develops ERNA-101, an allogeneic iPSC-derived mesenchymal stem cell therapy engineered to secrete IL-7 and IL-15, for platinum-resistant ovarian cancer.

Stories only

SEC EDGAR ClinicalTrials.gov

8-KSep 16Latest SEC filing, period to Sep 16

Sep 16Latest story

September 2026

Ernexa Therapeutics appoints Robert J. Spiegel to board of directors

Sep 16PeopleErnexa Therapeutics Inc.